WASHINGTON — A dog named Ralph, diagnosed with dementia in February 2025, contributed to canine aging research through cognitive testing and postmortem brain analysis. His case provided insights into potential dementia treatments for both dogs and humans.
Ralph was adopted by the Rowe family in 2012. In 2024, Ralph began to exhibit behavioral changes, including anxiety, confusion, and pacing at a family residence. Following his diagnosis, Ralph enrolled in the Dog Aging Project, a collaborative research initiative involving dog owners, veterinarians, and scientists. Comparative psychologist Evan MacLean administered a short-term memory test to Ralph involving a concealed treat.
An MRI scan in August revealed enlarged fluid-filled pockets in Ralph's brain compared to a healthy canine brain. McGrath stated that the white areas visible in the scan represented fluid bathing the brain, which normally should be difficult to observe. She added that Ralph's brain had shrunk, and the empty space filled with fluid. McGrath noted that there is no broadly effective treatment currently available for dementia in humans with Alzheimer's disease or in dogs.
Julie Moreno, a molecular biologist at Colorado State University, conducted a pilot study on 12 dogs showing signs of dementia, testing the drug rapamycin. Post-mortem examinations indicated that dogs administered rapamycin exhibited fewer microglial cells, which are linked to inflammation in dementia. Ralph's brain tissue showed a lower concentration of microglial cells compared to tissue from dogs in the placebo group. Ralph died in December.
Tara Rowe said, "Ralph can be a part of a study that helps to figure out what could work for dementia in dogs." She added, "The fact that Ralph was able to contribute to science and to be part of exploring the unknown of dementia means more to us than we can fully put into words."